- Chemotherapy,
- Adjuvant Chemotherapy,
- Radiation Therapy,
- Surgery,
- Targeted Therapy
Latin America Gastric Cancer Treatment Market size was valued at USD million in 2021 and is expected to reach a value of USD million by 2028, growing at a significant CAGR during the forecast period 2022 to 2028. The global market provides a detailed overview of the gastric cancer treatment market and that can be segmented by treatment, cancer type, and end user. By treatment, the gastric cancer treatment market has been segmented into chemotherapy, adjuvant chemotherapy, radiation therapy, surgery, and targeted therapy. The chemotherapy segment is likely to be the largest and fastest-growing segment in terms of treatment. Based on cancer type, the gastric cancer treatment market is segmented into laryngeal cancer, lip and oral cavity cancer, nasopharyngeal cancer, oropharyngeal cancer, salivary gland cancer, and others. Among these, the laryngeal cancer segment is expected to have the fastest-growing market during the forecast period 2022-2028. On the basis of end-users, the market is segregated into hospitals, clinics, ambulatory surgical centers, and specialized cancer treatment centers. The hospitals segment held a considerable market share during the forecast period.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
Some of the key factors fueling the market growth include quick regulatory agency approval of gastric cancer medications, the rapid development of sophisticated diagnostic equipment, increased public awareness of the signs and causes of gastric cancer, and introduction of novel therapies for metastatic stomach cancer.
The latin america gastric cancer treatment market is projected to expand at a CAGR of x% during the forecast period.
The major players in the global gastric cancer treatment market are Abbott Laboratories, Inc., AstraZeneca plc, Eli Lilly and Company, Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Amgen, Inc, Celgene corporation, Novartis AG, Jiangsu Hengrui Medicine Co., Ltd, TAIHO PHARMACEUTICAL CO., LTD, Celltrion Inc., Bristol-Myers Squibb Company, Bayer AG and Merck & Co., Inc.
1. Executive Summary |
2. Latin America Gastric Cancer Treatment Market Introduction |
2.1. Latin America Gastric Cancer Treatment Market – Taxonomy |
2.2. Latin America Gastric Cancer Treatment Market –Definitions |
2.2.1. By Treatment |
2.2.2. By Cancer Type |
2.2.3. By End User |
2.2.4. By Country |
3. Latin America Gastric Cancer Treatment Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Epidemiology Studies |
3.6. Pipeline Analysis |
3.7. Clinical Trails Analysis |
3.8. Drug Approvals and Estimated Launch Years |
3.9. Latin America Gastric Cancer Treatment Market Dynamic Factors - Impact Analysis |
3.10. Latin America Gastric Cancer Treatment Market – Competition Landscape |
4. Latin America Gastric Cancer Treatment Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 |
4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Latin America Gastric Cancer Treatment Market, By Treatment, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
5.1. Chemotherapy |
5.1.1. Programmed Cell Death Protein 1 (PD-1) Inhibitors |
5.1.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.1.3. Market Opportunity Analysis |
5.1.2. Human Epidermal Growth Factor Receptor (HER2) Antagonists |
5.1.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.2.3. Market Opportunity Analysis |
5.1.3. Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists |
5.1.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3.3. Market Opportunity Analysis |
5.1.4. Others |
5.1.4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.4.3. Market Opportunity Analysis |
5.2. Adjuvant Chemotherapy |
5.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Radiation Therapy |
5.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Surgery |
5.4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Targeted Therapy |
5.5.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
6. Latin America Gastric Cancer Treatment Market Forecast, By Cancer Type, 2017 - 2021 and Forecast, 2022 - 2028 |
6.1. Laryngeal Cancer |
6.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Lip and Oral Cavity Cancer |
6.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Nasopharyngeal Cancer |
6.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Oropharyngeal Cancer |
6.4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
6.5. Salivary Gland Cancer |
6.5.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.5.3. Market Opportunity Analysis |
6.6. Others |
6.6.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.6.3. Market Opportunity Analysis |
7. Latin America Gastric Cancer Treatment Market Forecast, By Cancer Type, 2017 - 2021 and Forecast, 2022 - 2028 |
7.1. Hospitals |
7.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Clinics |
7.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Ambulatory Surgical Centers |
7.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Specialized Cancer Treatment Centers |
7.4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
8. Latin America Gastric Cancer Treatment Market Forecast, By Country, 2017 - 2021 and Forecast, 2022 - 2028 |
8.1. Brazil |
8.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Mexico |
8.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Argentina |
8.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Rest of Latin America |
8.4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America Gastric Cancer Treatment Market – Opportunity Analysis Index, By Treatment, End User and Country 2020 – 2026 |
9. Brazil Gastric Cancer Treatment Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
9.1. By Treatment Analysis 2017 - 2021 and Forecast, 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
9.1.1. Chemotherapy |
9.1.1.1. Programmed Cell Death Protein 1 (PD-1) Inhibitors |
9.1.1.2. Human Epidermal Growth Factor Receptor (HER2) Antagonists |
9.1.1.3. Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists |
9.1.1.4. Others |
9.1.2. Adjuvant Chemotherapy |
9.1.3. Radiation Therapy |
9.1.4. Surgery |
9.1.5. Targeted Therapy |
9.2. By Cancer Type Analysis 2017 - 2021 and Forecast, 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
9.2.1. Laryngeal Cancer |
9.2.2. Lip and Oral Cavity Cancer |
9.2.3. Nasopharyngeal Cancer |
9.2.4. Oropharyngeal Cancer |
9.2.5. Salivary Gland Cancer |
9.2.6. Others |
9.3. By End User Analysis 2017 - 2021 and Forecast, 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
9.3.1. Hospitals |
9.3.2. Clinics |
9.3.3. Ambulatory Surgical Centers |
9.3.4. Specialized Cancer Treatment Centers |
9.4. Brazil Gastric Cancer Treatment Market – Opportunity Analysis Index, By Treatment, By Cancer and End User, 2020 – 2026 |
9.5. Brazil Gastric Cancer Treatment Market Dynamics – Opportunities |
10. Mexico Gastric Cancer Treatment Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
10.1. By Treatment Analysis 2017 - 2021 and Forecast, 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.1.1. Chemotherapy |
10.1.1.1. Programmed Cell Death Protein 1 (PD-1) Inhibitors |
10.1.1.2. Human Epidermal Growth Factor Receptor (HER2) Antagonists |
10.1.1.3. Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists |
10.1.1.4. Others |
10.1.2. Adjuvant Chemotherapy |
10.1.3. Radiation Therapy |
10.1.4. Surgery |
10.1.5. Targeted Therapy |
10.2. By Cancer Type Analysis 2017 - 2021 and Forecast, 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.2.1. Laryngeal Cancer |
10.2.2. Lip and Oral Cavity Cancer |
10.2.3. Nasopharyngeal Cancer |
10.2.4. Oropharyngeal Cancer |
10.2.5. Salivary Gland Cancer |
10.2.6. Others |
10.3. By End User Analysis 2015 – 2019 and Forecast 2020 – 2026 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.3.1. Hospitals |
10.3.2. Clinics |
10.3.3. Ambulatory Surgical Centers |
10.4. Specialized Cancer Treatment CentersMexico Gastric Cancer Treatment Market – Opportunity Analysis Index, By Treatment, By Cancer Type and End User, 2022 – 2028 |
10.5. Mexico Gastric Cancer Treatment Market Dynamics – Opportunities |
11. Argentina Gastric Cancer Treatment Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
11.1. By Treatment Analysis 2017 - 2021 and Forecast, 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.1.1. Chemotherapy |
11.1.1.1. Programmed Cell Death Protein 1 (PD-1) Inhibitors |
11.1.1.2. Human Epidermal Growth Factor Receptor (HER2) Antagonists |
11.1.1.3. Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists |
11.1.1.4. Others |
11.1.2. Adjuvant Chemotherapy |
11.1.3. Radiation Therapy |
11.1.4. Surgery |
11.1.5. Targeted Therapy |
11.2. By Cancer Type Analysis 2017 - 2021 and Forecast, 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.2.1. Laryngeal Cancer |
11.2.2. Lip and Oral Cavity Cancer |
11.2.3. Nasopharyngeal Cancer |
11.2.4. Oropharyngeal Cancer |
11.2.5. Salivary Gland Cancer |
11.2.6. Others |
11.3. By End User Analysis 2017 - 2021 and Forecast, 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.3.1. Hospitals |
11.3.2. Clinics |
11.3.3. Ambulatory Surgical Centers |
11.4. Argentina Countries Gastric Cancer Treatment Market – Opportunity Analysis Index, By Treatment, By Cancer Type and End User, 2020 – 2028 |
11.5. Argentina Gastric Cancer Treatment Market Dynamics – Opportunities |
12. Rest of Latin America Gastric Cancer Treatment Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn) |
12.1. By Treatment Analysis 2017 - 2021 and Forecast, 2022 - 2028Â by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.1.1. Chemotherapy |
12.1.1.1. Programmed Cell Death Protein 1 (PD-1) Inhibitors |
12.1.1.2. Human Epidermal Growth Factor Receptor (HER2) Antagonists |
12.1.1.3. Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists |
12.1.1.4. Others |
12.1.2. Adjuvant Chemotherapy |
12.1.3. Radiation Therapy |
12.1.4. Surgery |
12.1.5. Targeted Therapy |
12.2. By Cancer Type Analysis 2017 - 2021 and Forecast, 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.2.1. Laryngeal Cancer |
12.2.2. Lip and Oral Cavity Cancer |
12.2.3. Nasopharyngeal Cancer |
12.2.4. Oropharyngeal Cancer |
12.2.5. Salivary Gland Cancer |
12.2.6. Others |
12.3. By End User Analysis 2017 - 2021 and Forecast, 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.3.1. Hospitals |
12.3.2. Clinics |
12.3.3. Ambulatory Surgical Centers |
12.4. Rest of Latin America Countries Gastric Cancer Treatment Market – Opportunity Analysis Index, By Treatment, By Cancer Type and End User, 2022 – 2028 |
12.5. Rest of Latin America Gastric Cancer Treatment Market Dynamics – Opportunities |
13. Competition Landscape |
13.1. Strategic Dashboard of Top Market Players |
13.2. Company Profiles (Introduction, Financial Analysis, Product Type & Service Offerings, Key Developments, Strategies, and SWOT Analysis) |
13.2.1. Abbott Laboratories, Inc. |
13.2.2. AstraZeneca plc |
13.2.3. Eli Lilly and Company |
13.2.4. Hoffmann-La Roche Ltd |
13.2.5. GlaxoSmithKline plc |
13.2.6. Amgen, Inc |
13.2.7. Celgene corporation |
13.2.8. Novartis AG |
13.2.9. Jiangsu Hengrui Medicine Co., Ltd |
13.2.10. TAIHO PHARMACEUTICAL CO., LTD |
13.2.11. Celltrion Inc. |
13.2.12. Bristol-Myers Squibb Company |
13.2.13. Bayer AG |
13.2.14. Merck & Co., Inc. |
14. Research Methodology |
15. Key Assumptions and Acronyms |